← back to search

Meixing Yu

Huaihua University · CN
Area of research
Immunology · Infectious Diseases
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Epigenetics and DNA Methylation, Reproductive System and Pregnancy, and Immune Response and Inflammation.
h-index
14
citations
1,492
works
26
NIH funding
primary concept
email

Recent publications

Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers
Cell Reports Medicine 2024cited by 23position: middledoi
Identification of Immune-Related Key Genes in Ovarian Cancer Based on WGCNA
Frontiers in Genetics 2021cited by 38position: lastdoi
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Nature Materials 2017cited by 878position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hui Luo · Jiangnan University1 papers (2024–2024)Zhihai Liu · Guangzhou Medical University1 papers (2024–2024)Xiaoxue Zheng · South China Agricultural University1 papers (2024–2024)Kun Shi · Xuzhou Medical College1 papers (2024–2024)Yang Zhao · Peking University1 papers (2024–2024)Yongqiang Zhang · Weifang Medical University1 papers (2024–2024)Xinxin Xiong · Guangzhou Medical University1 papers (2021–2021)Shanyun Wu · Guangzhou Medical University1 papers (2021–2021)Manson Fok · Zhuhai People's Hospital1 papers (2024–2024)Kun Li · Wenzhou Medical University1 papers (2024–2024)Hong Huang · Anhui Medical University1 papers (2024–2024)Xiaoqiong Gu · Guangzhou Medical University1 papers (2024–2024)Johnson Yiu‐Nam Lau · Hong Kong Baptist University1 papers (2024–2024)Kang Zhang · Wenzhou Medical University1 papers (2024–2024)Lingchuan Guo · Soochow University1 papers (2024–2024)Fei Liu · Shenzhen Sixth People's Hospital1 papers (2024–2024)Chengbin Guo · Guangzhou Medical University1 papers (2024–2024)Qingli Quan · Huaihua University1 papers (2021–2021)Yong Wu · Nantong University1 papers (2024–2024)Taorui Wang · Guangzhou Medical University1 papers (2024–2024)